Sign in Subscribe
Cancer

Nanotechnology Breakthrough Offers Promising Strategy for Overcoming Immunosuppression in Tumor Immunotherapy

Strategic Insights

— 1 min read

Researchers from Tianjin Medical University Cancer Institute and Hospital have developed a multifunctional nanoplatform, IN@OMV-PDL1nb, designed to simultaneously inhibit tumor-associated macrophages (TAMs) and the immune checkpoint molecule PD-L1 within the tumor microenvironment (TME). This innovative approach effectively alleviates immune suppression induced by TAMs and PD-L1, offering a promising strategy for tumor immunotherapy. In murine tumor models, IN@OMV-PDL1nb significantly inhibited tumor growth, increased survival, and enhanced antigen presentation and T cell recruitment.

Key Takeaways:

  • A multifunctional nanoplatform, IN@OMV-PDL1nb, has been designed to inhibit tumor-associated macrophages (TAMs) and the immune checkpoint molecule PD-L1 within the tumor microenvironment (TME).
  • IN@OMV-PDL1nb effectively alleviates immune suppression induced by TAMs and PD-L1, offering a promising strategy for tumor immunotherapy.
  • In murine tumor models, IN@OMV-PDL1nb significantly inhibited tumor growth and increased survival.
  • The nanoplatform enhances antigen presentation and T cell recruitment, and induces robust adaptive immunity.
  • IN@OMV-PDL1nb was engineered through genetic modifications to express a matrix metalloproteinase-2 (MMP-2)-responsive peptide and the PD-L1 nanobody on its surface, while IRG1-IN-1 was loaded into its internal cavity.
  • The biomineralization of calcium phosphate (CaP) on the surface further enhances the nanoplatform's functionality.

Statistics:

  • The study used murine tumor models to evaluate the efficacy of IN@OMV-PDL1nb.
  • IN@OMV-PDL1nb significantly inhibited tumor growth compared to controls.
  • The nanoplatform increased survival rates in murine tumor models.
  • IN@OMV-PDL1nb enhanced antigen presentation and T cell recruitment in murine tumor models.
  • The biomineralization of CaP on the surface of the nanoplatform improved its functionality.

Sources:

  • Reprogramming Tumor-associated Macrophages and Blocking Pd-l1 Via Engineered Outer Membrane Vesicles To Enhance T Cell Infiltration and Cytotoxic Functions. Journal of Nanobiotechnology, 2025;23(1).
  • NewsRx. Reports on Nanobodies from Tianjin Medical University Cancer Institute and Hospital Provide New Insights (Reprogramming Tumor-associated Macrophages and Blocking Pd-l1 Via Engineered Outer Membrane Vesicles To Enhance T Cell Infiltration and ...). Immunotherapy Weekly. August 13, 2025; p 71.

Read more